Eli Lilly and Company (Lilly) has revealed plans to launch a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with Covid-19, in partnership with major local institutions in New Mexico. The US pharma giant said that carrying out the study in New Mexico will help in the collection of data on the effectiveness and […]